These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Henry C; Wilson JA Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299 [No Abstract] [Full Text] [Related]
4. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor. Iwuagwu CU; Riley D; Bonoma RA Am J Med; 2000 Apr; 108(6):517-8. PubMed ID: 10866587 [No Abstract] [Full Text] [Related]
5. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Borges N Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845 [TBL] [Abstract][Full Text] [Related]
8. Update on "open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder". Moroz G; Magni G; Fava M J Clin Psychopharmacol; 2000 Apr; 20(2):285. PubMed ID: 10770481 [No Abstract] [Full Text] [Related]
9. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191 [TBL] [Abstract][Full Text] [Related]
10. First COMT inhibitor approved for Parkinson's disease. Am J Health Syst Pharm; 1998 Mar; 55(6):524, 526. PubMed ID: 9544322 [No Abstract] [Full Text] [Related]
14. [Comparison of the safety of the medicinal product in the European Union and the United States, tolcapone (Tasmar) -- COMT inhibitor as the analyzed example]. Konopka M; Członkowski A Neurol Neurochir Pol; 2005; 39(6):490-6. PubMed ID: 16355307 [TBL] [Abstract][Full Text] [Related]
15. Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Martignoni E; Cosentino M; Ferrari M; Porta G; Mattarucchi E; Marino F; Lecchini S; Nappi G Neurology; 2005 Dec; 65(11):1820-2. PubMed ID: 16344532 [TBL] [Abstract][Full Text] [Related]
16. Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication. Blum MW; Siegel AM; Meier R; Hess K Eur Neurol; 2001; 46(3):158-60. PubMed ID: 11598337 [No Abstract] [Full Text] [Related]
17. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs. Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845 [TBL] [Abstract][Full Text] [Related]
18. Tolcapone: more than meets the eye? Deleu D; Hanssens Y Am J Health Syst Pharm; 2000 Aug; 57(16):1534. PubMed ID: 10965399 [No Abstract] [Full Text] [Related]
19. [Tolcapone in the management of Parkinson's disease]. Pilipovich AA; Golubev VL Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(6):71-8. PubMed ID: 18688929 [No Abstract] [Full Text] [Related]
20. A preclinical re-evaluation of the safety profile of tolcapone. Borroni E; Cesura AM; Gatti S; Gasser R Funct Neurol; 2001; 16(4 Suppl):125-34. PubMed ID: 11996507 [No Abstract] [Full Text] [Related] [Next] [New Search]